Symbiotec Pharmalab Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹10,553 Cr
- P/E
- 71.38
- ROE
- 11.74%
- PEG
- 1.01
- Price to sales
- 12.14
- Debt to equity
- 0.25
- 52W high / low
- ₹1,194 / ₹934
- Sales growth (5Y)
- 6.55%
- EBITDA margin
- 27.46%
- Net profit margin
- 13.27%
- Promoter holding
- 33.28%
- Sales (last year)
- ₹869 Cr
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.[1]
Guidance scorecard · Q2 FY27 call
What Symbiotec Pharma's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
20–40%- API business is expected to grow at a high single-digit to low double-digit rate annually, driven primarily by volume growth and improved product and geography mix.
- The steroid hormone segment remains a strong base, with continued potential expansion into new products and geographies, supporting consistent demand and pricing.
- Complex injectable business anticipates recurring milestone revenues year-on-year, with sales and profit expected to kick in by the end of the next fiscal year.
- Fermentation CDMO vertical has substantial growth headroom with existing 10-year take-or-pay contracts; Phase 1 expansion (~750 KL capacity) will scale revenues in FY28-'29 and beyond with multi-million liter capacities planned.
2 more points from Symbiotec Pharma's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Symbiotec Pharma said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Capex investment for H1 FY27 stood at INR113 crores; net debt as of Sept 30 at INR314 crores.
- Committed to corporate-level capex of INR200-300 crores annually, including biologics and biomanufacturing expansion.
- Large capex for bio-CDMO business (increase from 600 KL to 750 KL capacity) backed by long-term take-or-pay customer agreements.
- Significant capex for new biologics plant (~INR100 crores) focusing on insulin and analogs, with some delays due to regulatory updates.
- Capex is partly shared with customers via strategic partnerships and milestone payments.
- Future expansions planned at Ujjain fermentation CDMO site; acquired additional 40 acres to create a 70-72 acre mega facility.
2 more points from Symbiotec Pharma's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
PlannedSee what Symbiotec Pharma said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
- Symbiotec signed a legally binding 10-year take-or-pay agreement with a large European alternate protein customer for multi-million liter fermentation capacity, including Phase 0 (existing 100 KL capacity), Phase 1 (750 KL additional capacity), and…
- Phase 0 production expected within the fiscal year; Phase 1 production to start next fiscal year.
- The agreement is exclusive for the European customer covering global distribution, including US, Europe, and potentially Indian markets.
- Multiple advanced discussions are ongoing with around 4 biomanufacturing customers for new CDMO opportunities.
- The company has a multi-tens of millions USD milestone payment-based tie-up for injectable products focused on the US market, with discussions active for Europe and China.
2 more points from Symbiotec Pharma's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Symbiotec Pharma.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Symbiotec Pharma
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Symbiotec Pharma
Shareholding breakup across reporting periods.
| Sep 2026 | |
|---|---|
| Promoters + | 33.28% |
| FIIs + | 3.79% |
| DIIs + | 33.17% |
| Public + | 29.77% |
| No. of Shareholders | 81,747 |
Financials of Symbiotec Pharma
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Sales + | 203 | 196 | 245 | 218 | 280 |
| YoY Sales growth | +7% | +43% | |||
| Expenses + | 145 | 145 | 183 | 173 | 188 |
| Operating Profit | 58 | 50 | 62 | 45 | 92 |
| OPM % | 29% | 26% | 25% | 21% | 33% |
| Other Income + | 3 | 0 | 0 | 0 | 0 |
| Interest | 5 | 6 | 7 | 6 | 6 |
| Depreciation | 11 | 11 | 20 | 22 | 22 |
| Profit before tax | 45 | 33 | 35 | 18 | 64 |
| Tax % | 33% | 43% | 22% | 20% | 19% |
| Net Profit + | 30 | 19 | 28 | 14 | 52 |
| EPS in Rs | 46.99 | 30.18 | 4.39 | 2.24 | 8.05 |
Financials of Symbiotec Pharma
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 633 | 682 | 567 | 716 | 752 | 869 |
| Sales growth | +8% | -17% | +26% | +5% | +16% | |
| Expenses + | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31% | 19% | 12% | 24% | 27% | 27% |
| Other Income + | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28% | 27% | 38% | 23% | 34% | 28% |
| Net Profit + | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 22.54 | 14.17 | 4.29 | 18.29 | 151.98 | 17.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Symbiotec Pharma
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 | 1,348 |
| Borrowings + | 47 | 65 | 218 | 247 | 544 | 391 | 336 |
| Other Liabilities + | 200 | 152 | 151 | 326 | 220 | 240 | 347 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 | 2,044 |
| Fixed Assets + | 261 | 280 | 299 | 448 | 438 | 1,120 | 1,091 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 | 138 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 | 4 |
| Other Assets + | 474 | 490 | 504 | 628 | 572 | 592 | 811 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 | 2,044 |
Financials of Symbiotec Pharma
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from Investing Activity + | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from Financing Activity + | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 112% | 36% | 124% | 129% | 40% | 99% |
Financials of Symbiotec Pharma
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | 18% | 6% | 16% | 14% | 13% |
Guidance history
How Symbiotec Pharma's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Flat | Planned | Planned | — |
| Q1 FY27 call → | 20–40% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Symbiotec Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Vineet Laborator (Q2 FY27)
Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27
- Balaxi Pharma (Q2 FY27)
34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Alkem Lab (Q2 FY27)
Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres
- Caplin Point Laboratories Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor
